Pyxis Oncology will deliver preliminary Phase 1 data in the fourth quarter of 2025 for micvotabart pelidotin, a first-in-concept...

Krystal Biotech reported third-quarter 2025 net product revenue of $97.8 million from Vyjuvek, expanded the U.S. label to include...

Kamada will report third-quarter and nine-month 2025 results before the U.S. market opens on November 10, with an investor...

Psyence Biomedical has made a $3.5 million follow-on investment in Psylabs, a producer of purified psychedelic active pharmaceutical ingredients,...

TG Therapeutics reported third-quarter 2025 revenue of $161.7 million, including $152.9 million in U.S. Briumvi net sales. It raised...

BioCryst posted a profitable third quarter on the back of Orladeyo, raised full‑year guidance, completed the sale of its...

BioNTech raised its 2025 revenue guidance to €2.6–2.8 billion and tightened spending plans after reporting third-quarter revenues of €1.52...

Nanobiotix has secured up to $71 million in non-dilutive financing from Healthcare Royalty, anchored to future economics from its...

DXS International posted audited results for the year ended 30 April 2025, reporting a 5% revenue rise to £3.47...

Nxera Pharma has unveiled a proprietary pipeline centered on obesity and chronic weight management, led by a differentiated oral...